Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease.

Niels Søndergaard HeinrichRune Ploegstra PedersenMark Bitsch VestergaardUlrich LindbergUlrik Bjørn AndersenBryan HaddockTine Willum HansenAlessia FornoniHenrik Bo Wiberg LarssonEllen Burgess

Published in: Diabetes, obesity & metabolism (2023)

Ezetimibe did not reduce the UACR or kidney-PF on top of modern T2D management. However, kidney-PF was reduced with ezetimibe in participants with high baseline kidney-PF.

Keyphrases

chronic kidney disease
adipose tissue
end stage renal disease
fatty acid